Perceptic, a London-based startup, has raised $12 million in seed funding to develop an integrated AI platform aimed at revolutionizing the drug development process, which is currently hindered by fragmented systems. This initiative seeks to streamline the journey of a drug from initial discovery through clinical trials, addressing inefficiencies that plague many pharmaceutical companies.
The founders of Perceptic, who previously played pivotal roles in developing Palantir’s AI products for life sciences, aim to create a cohesive intelligence layer that connects various stages of drug development. Unlike existing AI solutions that focus on isolated tasks—such as literature review or trial design—Perceptic’s system is designed to ensure that insights gained during earlier phases inform later decisions, mitigating the risk of lost information during departmental transitions.
Perceptic's platform utilizes AI agents tailored to different data types, integrating public knowledge, proprietary research, and external datasets into a unified decision-making framework. This innovation allows clients to significantly reduce the time required for scientific due diligence and enhance the scale of asset screening and clinical data extraction. The company is already operational with several high-profile pharmaceutical clients, including CSL.
As the AI in drug discovery market is projected to grow substantially, reaching over $8.5 billion by 2030, Perceptic’s approach stands out by focusing on the interconnectedness of the entire drug development lifecycle rather than competing solely in specific stages. However, a critical challenge remains: whether large pharmaceutical companies will adopt a comprehensive operating system or continue to rely on disparate solutions for individual workflows. This decision could shape the future landscape of pharmaceutical AI significantly.